Skip to main content
. 2021 Aug 9;2021:1412663. doi: 10.1155/2021/1412663

Table 1.

Characteristics of Crohn's disease patients.

Results (n = 122) Non-5-ASA (n = 30) 5-ASA (n = 92) P value
Age, median (IQR) 33.0 (26.0–46.0) 32.5 (20.5–40.3) 33.5 (28.0–46.0) 0.082
Age at diagnosis, median (IQR) 27.0 (21.0–40.0) 28.0 (16.0–39.0) 27.0 (22.0–41.8) 0.184
Female, n (%) 50 (41.0) 12 (40.0) 38 (41.3) 0.900
Smoking, n (%) 0.330
 Never 95 (77.9) 25 (83.3) 70 (76.1)
 Former 2 (1.6) 1 (3.3) 1 (1.1)
 Current 25 (20.5) 4 (13.3) 21 (22.8)
Age at diagnosis, n (%) 0.070
A1 17 (13.9) 8 (26.7) 9 (9.8)
A2 76 (62.3) 17 (56.7) 59 (64.1)
A3 29 (23.8) 5 (16.7) 24 (26.1)
Location at diagnosis, n (%) 0.753
L1 24 (19.7) 5 (16.7) 19 (20.7)
L2 50 (41.0) 14 (46.7) 36 (39.1)
L3 48 (39.3) 11 (36.7) 37 (40.2)
L4 involvement 8 (6.6) 3 (10.0) 2 (2.2) 0.095
Behaviour at diagnosis, n (%) 0.403
B1 87 (71.3) 23 (76.7) 64 (69.6)
B2 30 (24.6) 5 (16.7) 25 (27.2)
B3 5 (4.1) 2 (6.7) 3 (3.3)
Perianal disease at diagnosis, n (%) 5 (4.1) 1 (3.3) 4 (4.3) 1.000
Appendicectomy, n (%) 31 (25.4) 8 (26.7) 23 (25.0) 0.856
Elevated ESR at diagnosis, n (%) 73 (59.8) 19 (63.3) 54 (58.7) 0.653
CDAI at diagnosis, median (IQR) 171.0 (102.0–259.5) 161.0 (100.0–342.0) 173.0 (102.0–246.0) 0.562
Cumulative exposures for treatment, n (%)
 5-Aminosalicylic acid 92 (75.4)
 Corticosteroid 68 (55.7) 15 (50.0) 53 (57.6) 0.466
 Immunomodulators 64 (52.5) 13 (43.3) 51 (55.4) 0.249
 Biologics 70 (57.4) 18 (60.0) 52 (56.5) 0.738

IQR, interquartile range; ESR, erythrocyte sedimentation rate; CDAI: Crohn's disease activity index; 5-ASA, 5-aminosalicylic acid.